Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity
- PMID: 31507071
- PMCID: PMC6992499
- DOI: 10.1002/acr.24063
Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity
Abstract
Objective: Lupus low disease activity state (LLDAS) is a potential treat-to-target goal in systemic lupus erythematosus (SLE). This study determined predictors of time to reach LLDAS in a longitudinal cohort.
Methods: Patients were grouped according to LLDAS status at cohort entry. Those who did not satisfy LLDAS at cohort entry were analyzed prospectively. The Kaplan-Meier approach was used to estimate the time to LLDAS. Cox regression was used to identify patient characteristics that were associated with time to LLDAS.
Results: The probability of LLDAS attainment within 1 year was 52% for Caucasians, 36% for African Americans, and 33% for SLE patients with renal involvement. The median time to LLDAS was 1.1 years. In multivariable models, African American ethnicity, baseline prednisone >10 mg daily, hypocomplementemia, baseline damage, and baseline renal activity remained significant predictors of longer time to attain LLDAS, while disease duration <1 year and cutaneous activity were associated with earlier attainment.
Conclusion: LLDAS is potentially attainable in the majority of SLE patients. The time to LLDAS was found to be longer in African American patients with SLE. Characteristics of African American patients with SLE, such as renal activity and hypocomplementemia, were also independent predictors of slower attainment of LLDAS. These findings point to the need to include African American patients with SLE in both clinical and pharmaceutical research.
© 2019, American College of Rheumatology.
Conflict of interest statement
Figures
Similar articles
-
Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).Lupus. 2019 Dec;28(14):1648-1655. doi: 10.1177/0961203319886028. Epub 2019 Nov 6. Lupus. 2019. PMID: 31694446 Free PMC article.
-
Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State in Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.J Rheumatol. 2024 Aug 1;51(8):790-797. doi: 10.3899/jrheum.2023-0900. J Rheumatol. 2024. PMID: 38490668
-
Transitioning from Lupus Low Disease Activity State to remission in systemic lupus erythematosus: real-world evidence.Front Immunol. 2025 Mar 20;16:1546306. doi: 10.3389/fimmu.2025.1546306. eCollection 2025. Front Immunol. 2025. PMID: 40181969 Free PMC article.
-
Targeting DORIS Remission and LLDAS in SLE: A Review.Rheumatol Ther. 2023 Dec;10(6):1459-1477. doi: 10.1007/s40744-023-00601-w. Epub 2023 Oct 5. Rheumatol Ther. 2023. PMID: 37798595 Free PMC article. Review.
-
Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus.Autoimmun Rev. 2022 Oct;21(10):103165. doi: 10.1016/j.autrev.2022.103165. Epub 2022 Aug 2. Autoimmun Rev. 2022. PMID: 35931316 Review.
Cited by
-
Lupus Cohorts.Rheum Dis Clin North Am. 2021 Aug;47(3):457-479. doi: 10.1016/j.rdc.2021.04.009. Epub 2021 Jun 10. Rheum Dis Clin North Am. 2021. PMID: 34215374 Free PMC article. Review.
-
Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort.Lupus Sci Med. 2024 Dec 11;11(2):e001206. doi: 10.1136/lupus-2024-001206. Lupus Sci Med. 2024. PMID: 39663154 Free PMC article.
-
Cardiac conduction disturbances in rheumatologic disease: a cross-sectional study.Am J Cardiovasc Dis. 2022 Feb 15;12(1):31-37. eCollection 2022. Am J Cardiovasc Dis. 2022. PMID: 35291510 Free PMC article.
-
Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.Clin Rheumatol. 2023 Jun;42(6):1655-1664. doi: 10.1007/s10067-023-06533-8. Epub 2023 Feb 13. Clin Rheumatol. 2023. PMID: 36780064
-
Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors.Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v29-v38. doi: 10.1093/rheumatology/keaa382. Rheumatology (Oxford). 2020. PMID: 33280012 Free PMC article. Review.
References
-
- van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958–67. - PubMed
-
- Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016;75:1615–21. - PubMed
-
- Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 2018;77:104–10. - PubMed
-
- Tsang ASMW, Bultink IE, Heslinga M, Voskuyl AE. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford) 2017;56:121–8. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical